Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell'Italia Meridionale. (GOIM) Objectively confirmed response rate Time-to- progression

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A MULTICENTER PHASE II STUDY TO EVALUATE ACTIVITY AND TOLERABILITY OF CISPLATIN (CDDP) AND FOTEMUSTINE (FTM) COMBINATION IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES PRIMARY ENDPOINT: Activity and tolerability of Cisplatin and Fotemustine combination with radiotherapy in paztients with advanced NSCLC and brain metastases not amenable to definitive locoregional tre...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

multicenter phase II study to evaluate palonosetron +desametasone in the prevention of nausea and vomiting in patientes resected for colon cancer and treated with moderate emetogenus chemotherapy to evaluate the efficacy of palonosetron + desametasone in the prevention of nausea and vomiting in patients treated with moderate emetogenous chemotherapy

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women To consider the activity of the chemoteraphic combination with the percentage of obiective responses

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

a multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in Her-2 neg. metastatic breast cancer studio di fase II, in pazienti affette da carcinoma della mammella metastatico Her-2 neg. e triple neg., I linea, utilizzando ABX e capecitabina the efficacy of combination in terms of responce rate; the progression free survival valutare l'attivitò di nab-paclitaxel (abraxane) in associazione a capecitabina (xeloda), in termini di rispo...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune